94 related articles for article (PubMed ID: 28065418)
21. Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.
Huang HS; Su HY; Li PH; Chiang PH; Huang CH; Chen CH; Hsieh MC
Sci Rep; 2018 May; 8(1):7485. PubMed ID: 29748589
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
Bellmunt J; Choueiri TK; Fougeray R; Schutz FA; Salhi Y; Winquist E; Culine S; von der Maase H; Vaughn DJ; Rosenberg JE
J Clin Oncol; 2010 Apr; 28(11):1850-5. PubMed ID: 20231682
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
[TBL] [Abstract][Full Text] [Related]
24. A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.
Apolo AB; Karzai FH; Trepel JB; Alarcon S; Lee S; Lee MJ; Tomita Y; Cao L; Yu Y; Merino MJ; Madan RA; Parnes HL; Steinberg SM; Rodriguez BW; Seon BK; Gulley JL; Arlen PM; Dawson NA; Figg WD; Dahut WL
Clin Genitourin Cancer; 2017 Feb; 15(1):77-85. PubMed ID: 27328856
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
26. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
[TBL] [Abstract][Full Text] [Related]
27. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
Pond GR; Bellmunt J; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Sonpavde G
Clin Genitourin Cancer; 2015 Feb; 13(1):71-9. PubMed ID: 24993933
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Sep; 14(9):828-32. PubMed ID: 17760750
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
[TBL] [Abstract][Full Text] [Related]
31. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.
Vassilakopoulou M; de la Motte Rouge T; Colin P; Ouzzane A; Khayat D; Dimopoulos MA; Papadimitriou CA; Bamias A; Pignot G; Nouhaud FX; Hurel S; Guy L; Bigot P; Roumiguié M; Rouprêt M;
Cancer; 2011 Dec; 117(24):5500-8. PubMed ID: 21638278
[TBL] [Abstract][Full Text] [Related]
32. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
Sonpavde G; Watson D; Tourtellott M; Cowey CL; Hellerstedt B; Hutson TE; Zhan F; Vogelzang NJ
Clin Genitourin Cancer; 2012 Mar; 10(1):1-5. PubMed ID: 22340630
[TBL] [Abstract][Full Text] [Related]
33. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
[TBL] [Abstract][Full Text] [Related]
34. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
35. Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma.
Han JJ; Kim YJ; Kim JW; Chang H; Lee JO; Lee KW; Jeong CW; Kim JH; Hong SK; Bang SM; Byun SS; Lee SE; Lee JS
Tumori; 2014; 100(4):439-45. PubMed ID: 25296594
[TBL] [Abstract][Full Text] [Related]
36. Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.
Hong JY; Choi MK; Uhm JE; Park MJ; Lee J; Park SH; Park JO; Kim WS; Kang WK; Lee HM; Choi HY; Lim H
Med Oncol; 2009; 26(2):186-92. PubMed ID: 18988001
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
[TBL] [Abstract][Full Text] [Related]
38. Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.
Heers H; DE Geeter P; Goebell PJ; Matz U; DE Schultz W; Edlich B; Retz M; Hegele A
Anticancer Res; 2017 Nov; 37(11):6437-6442. PubMed ID: 29061830
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
[TBL] [Abstract][Full Text] [Related]
40. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
Bambury RM; Benjamin DJ; Chaim JL; Zabor EC; Sullivan J; Garcia-Grossman IR; Regazzi AM; Ostrovnaya I; Apollo A; Xiao H; Voss MH; Iyer G; Bajorin DF; Rosenberg JE
Oncologist; 2015 May; 20(5):508-15. PubMed ID: 25845990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]